42.64 USD
+1.45 (+3.52%)
RIGL gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While RIGL has a great health rating, its profitability is only average at the moment. RIGL is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make RIGL suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
In the past year RIGL was profitable.
RIGL had a positive operating cash flow in the past year.
In the past 5 years RIGL reported 4 times negative net income.
In multiple years RIGL reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 46.72%, RIGL belongs to the top of the industry, outperforming 99.43% of the companies in the same industry.
RIGL has a Return On Equity of 96.34%. This is amongst the best in the industry. RIGL outperforms 99.43% of its industry peers.
RIGL's Return On Invested Capital of 63.44% is amongst the best of the industry. RIGL outperforms 99.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RIGL's Profit Margin of 40.17% is amongst the best of the industry. RIGL outperforms 96.79% of its industry peers.
RIGL's Operating Margin of 42.17% is amongst the best of the industry. RIGL outperforms 98.68% of its industry peers.
The Gross Margin of RIGL (93.10%) is better than 93.77% of its industry peers.
In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
RIGL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RIGL has been reduced compared to 5 years ago.
RIGL has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.48, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
RIGL's Altman-Z score of -0.48 is in line compared to the rest of the industry. RIGL outperforms 58.87% of its industry peers.
RIGL has a debt to FCF ratio of 0.88. This is a very positive value and a sign of high solvency as it would only need 0.88 years to pay back of all of its debts.
RIGL has a better Debt to FCF ratio (0.88) than 93.96% of its industry peers.
RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.25, RIGL is not doing good in the industry: 66.23% of the companies in the same industry are doing better.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -0.48 |
ROIC/WACC7.12
WACC8.91%
2.3 Liquidity
A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
With a Current ratio value of 2.28, RIGL is not doing good in the industry: 72.83% of the companies in the same industry are doing better.
A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
RIGL has a worse Quick ratio (2.14) than 72.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4307.14%, which is quite impressive.
The Revenue has grown by 79.13% in the past year. This is a very strong growth!
Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 24.77% on average per year.
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
Based on estimates for the next years, RIGL will show a very strong growth in Earnings Per Share. The EPS will grow by 36.89% on average per year.
RIGL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.70% yearly.
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y36.89%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
RIGL is valuated cheaply with a Price/Earnings ratio of 6.91.
Based on the Price/Earnings ratio, RIGL is valued cheaply inside the industry as 98.87% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of RIGL to the average of the S&P500 Index (26.87), we can say RIGL is valued rather cheaply.
The Price/Forward Earnings ratio is 9.70, which indicates a very decent valuation of RIGL.
Based on the Price/Forward Earnings ratio, RIGL is valued cheaply inside the industry as 98.49% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.46, RIGL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.91 | ||
| Fwd PE | 9.7 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.87% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, RIGL is valued cheaply inside the industry as 98.49% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.36 | ||
| EV/EBITDA | 4.79 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RIGL has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as RIGL's earnings are expected to grow with 80.91% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y116.3%
EPS Next 3Y80.91%
5. Dividend
5.1 Amount
RIGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:RIGL (1/6/2026, 2:51:38 PM)
42.64
+1.45 (+3.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.11%
Inst Owner Change0%
Ins Owners2.59%
Ins Owner Change0%
Market Cap773.92M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target46.24 (8.44%)
Short Float %15.98%
Short Ratio4.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)5.84%
PT rev (3m)18.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.6%
EPS NY rev (1m)0%
EPS NY rev (3m)17.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.91 | ||
| Fwd PE | 9.7 | ||
| P/S | 2.74 | ||
| P/FCF | 11.36 | ||
| P/OCF | 11.35 | ||
| P/B | 6.58 | ||
| P/tB | 8.39 | ||
| EV/EBITDA | 4.79 |
EPS(TTM)6.17
EY14.47%
EPS(NY)4.4
Fwd EY10.31%
FCF(TTM)3.75
FCFY8.8%
OCF(TTM)3.76
OCFY8.81%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -0.48 |
F-Score7
WACC8.91%
ROIC/WACC7.12
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y36.89%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year525.53%
EBIT Next 3Y109.33%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
What is the valuation status for RIGL stock?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
How financially healthy is RIGEL PHARMACEUTICALS INC?
The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.